Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
50 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Diabetic Peripheral Neuropathy - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Diabetic Peripheral Neuropathy - Pipeline Review, H2 2014', provides an overview of the Diabetic Peripheral Neuropathy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Peripheral Neuropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Peripheral Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Peripheral Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Diabetic Peripheral Neuropathy Overview 6 Therapeutics Development 7 Pipeline Products for Diabetic Peripheral Neuropathy - Overview 7 Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis 8 Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies 9 Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 10 Diabetic Peripheral Neuropathy - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Diabetic Peripheral Neuropathy - Products under Development by Companies 13 Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes 14 Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 15 Astellas Pharma Inc. 15 Pfizer Inc. 16 BioChemics, Inc. 17 ViroMed Co., Ltd. 18 Cebix Incorporated 19 Diabetic Peripheral Neuropathy - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 VM-202 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 PF-05089771 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 CBX-129801 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ASP-8477 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 benfotiamine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 epalrestat - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules for Oncology, CNS and Metabolic Disorders - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Diabetic Peripheral Neuropathy - Recent Pipeline Updates 40 Diabetic Peripheral Neuropathy - Dormant Projects 42 Diabetic Peripheral Neuropathy - Discontinued Products 43 Diabetic Peripheral Neuropathy - Product Development Milestones 44 Featured News & Press Releases 44 Aug 12, 2014: Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica Studies Conducted in China 44 Oct 18, 2013: Pfizer Reports Top-Line Results From Two Lyrica Capsules CV Phase 3b Studies 44 Nov 27, 2012: Intellipharmaceutics Announces Results Of Initial Phase I Clinical Trial Of Controlled-release Pregabalin 46 Aug 29, 2012: RegeneRx Reports That Thymosin Beta 4 Promotes Recovery Of Peripheral Neuropathy In Type II Diabetic Mice 46 Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 47 May 04, 2012: Pfizer Reports Top-Line Results From Phase III Trial Of Lyrica Capsules CV In Patients With Diabetic Peripheral Neuropathy 47 Feb 21, 2012: SK Biopharmaceuticals Initiates Phase II Trials In US 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2014 7 Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Diabetic Peripheral Neuropathy - Pipeline by Astellas Pharma Inc., H2 2014 15 Diabetic Peripheral Neuropathy - Pipeline by Pfizer Inc., H2 2014 16 Diabetic Peripheral Neuropathy - Pipeline by BioChemics, Inc., H2 2014 17 Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co., Ltd., H2 2014 18 Diabetic Peripheral Neuropathy - Pipeline by Cebix Incorporated, H2 2014 19 Assessment by Monotherapy Products, H2 2014 20 Number of Products by Stage and Target, H2 2014 22 Number of Products by Stage and Mechanism of Action, H2 2014 24 Number of Products by Stage and Route of Administration, H2 2014 26 Number of Products by Stage and Molecule Type, H2 2014 28 Diabetic Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H2 2014 40 Diabetic Peripheral Neuropathy - Dormant Projects, H2 2014 42 Diabetic Peripheral Neuropathy - Discontinued Products, H2 2014 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
